# Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease

> **NCT01925352** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Ischemic Heart Disease

## Interventions

- **DRUG:** Ad-HGF

## Key facts

- **NCT ID:** NCT01925352
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925352, "Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01925352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*